A
Alessandra Bologna
Publications - 29
Citations - 1836
Alessandra Bologna is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 10, co-authored 23 publications receiving 1227 citations.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata,Giovanni Scambia,Dionyssios Katsaros,Ciro Gallo,Eric Pujade-Lauraine,Sabino De Placido,Alessandra Bologna,Béatrice Weber,Francesco Raspagliesi,Pierluigi Benedetti Panici,Gennaro Cormio,Roberto Sorio,Maria Giovanna Cavazzini,Gabriella Ferrandina,Enrico Breda,V. Murgia,Cosimo Sacco,Saverio Cinieri,Vanda Salutari,Caterina Ricci,Carmela Pisano,Stefano Greggi,Rossella Lauria,Domenica Lorusso,Claudia Marchetti,Luigi Selvaggi,Simona Signoriello,Maria Carmela Piccirillo,Massimo Di Maio,Francesco Perrone +29 more
TL;DR: In this paper, a study was conducted to assess whether a weekly schedule of carboplatin plus paclitaxel is more effective than the same drugs given every 3 weeks for patients with advanced ovarian cancer.
Journal ArticleDOI
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
Oriana Nanni,Dino Amadori,A. De Censi,Andrea Rocca,Andrea Freschi,Alessandra Bologna,Luca Gianni,F. Rosetti,Laura Amaducci,L Cavanna,Flavia Foca,Samanta Sarti,Patrizia Serra,Linda Valmorri,Paolo Bruzzi,Davide Corradengo,Alessandra Gennari,Myme investigators +17 more
TL;DR: The MYME trial failed to provide evidence in support of an anticancer activity of M in combination with first line CT in MBC, and a significantly shorter PFS was observed in insulin-resistant patients (HOMA ≥ 2.5).
Journal ArticleDOI
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Sandro Pignata,Domenica Lorusso,Florence Joly,Ciro Gallo,Nicoletta Colombo,Cristiana Sessa,Aristotelis Bamias,Vanda Salutari,Frédéric Selle,Simona Frezzini,Ugo De Giorgi,Patricia Pautier,Alessandra Bologna,Michele Orditura,Coraline Dubot,Angiolo Gadducci,S. Mammoliti,Isabelle Ray-Coquard,Elena Zafarana,Enrico Breda,Laure Favier,Antonio Ardizzoia,Saverio Cinieri,Rémy Largillier,Daniela Sambataro,Emmanuel Guardiola,Rossella Lauria,Carmela Pisano,Francesco Raspagliesi,Giovanni Scambia,Gennaro Daniele,Francesco Perrone,S Pignata,Domenica Lorusso,F Joly,C Gallo,N Colombo,C Sessa,A Bamias,V Salutari,F Selle,S Frezzini,U De Giorgi,P Pautier,A Bologna,M Orditura,C Dubot,A Gadducci,S Mammoliti,I Ray-Coquard,E Zafarana,E Breda,L Favier,A Ardizzoia,S Cinieri,R Largillier,D Sambataro,E Guardiola,R Lauria,C Pisano,F Raspagliesi,G Scambia,G Daniele,F Perrone +63 more
TL;DR: The value of continuing bevacizumab beyond progression after first-line treatment with the same drug is tested, as well as safety and progression-free survival, in women with recurrent ovarian cancer.
Journal ArticleDOI
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study
Sandro Pignata,Giovanni Scambia,Alessandra Bologna,Simona Signoriello,Ignace Vergote,Uwe Wagner,Domenica Lorusso,V. Murgia,Roberto Sorio,Gabriella Ferrandina,Cosimo Sacco,Gennaro Cormio,Enrico Breda,Saverio Cinieri,Donato Natale,Giorgia Mangili,Carmela Pisano,Sabrina Chiara Cecere,Marilena Di Napoli,Vanda Salutari,Francesco Raspagliesi,Laura Arenare,Alice Bergamini,Jane Bryce,Gennaro Daniele,Maria Carmela Piccirillo,Ciro Gallo,Francesco Perrone +27 more
TL;DR: MITO-8 supports the recommendation that PBC not be delayed in favor of an NPBC in patients with partially platinum-sensitive OC and should be used as a control arm in future trials of new drugs in this setting.